Pharmacogenetic issues in thorough QT trials

被引：7
作者：
Judson, Richard S.
Salisbury, Benjamin A.
Reed, Carol R.
Ackerman, Michael J.
机构：
[1] SpyroPharma, Guilford, CT USA
[2] Clin Data Inc, New Haven, CT USA
[3] Mayo Clin, Coll Med, Sudden Death Genom Lab, Rochester, MN USA
来源：
MOLECULAR DIAGNOSIS & THERAPY | 2006年 / 10卷 / 03期
关键词：
D O I：
10.1007/BF03256454
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Drug-induced QT prolongation (DI-LQT), through its associated arrhythmias, is a leading cause of drugs being withdrawn from the market. As a consequence, the US FDA and other regulatory agencies are mandating that all new drugs go through a so-called 'Thorough QT' (TQT) study to evaluate the potential for 'QT liability', specifically the potential for a drug to cause a discernible increase in the QT interval. Several genetic factors that modulate the risk of DI-LQT have been discovered. These are genes responsible for the congenital long QT syndrome, drug metabolism genes (mainly CYP2D6 and CYP3A4), and genes in other regulatory pathways. Here, we briefly review the links between genetic variants and drug-induced QT risk, and propose approaches to consider for using pharmacogenetics in planning and analyzing TQT studies.
引用
收藏
页码：153 / 162
页数：10
相关论文
共 76 条
[11]   Gender differences in heart rate before and after autonomic blockade: Evidence against an intrinsic gender effect [J].
Burke, JH ;
Goldberger, JJ ;
Ehlert, FA ;
Kruse, JT ;
Parker, MA ;
Kadish, AH .
AMERICAN JOURNAL OF MEDICINE, 1996, 100 (05) :537-543
[12]  
Camm AJ, 2004, ACQUIRED LONG QT SYN
[13]  
Carlson A M, 1996, J Am Pharm Assoc (Wash), VNS36, P263
[14]  
*COMM PROP MED PRO, 1997, POINTS CONS ASS POT
[15]  
CROTTI L, 2005, HEART RHYTHM S, V2, pS111
[16]   Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients [J].
Curtis, LH ;
Ostbye, T ;
Sendersky, V ;
Hutchison, S ;
Lapointe, NMA ;
Al-Khatib, SM ;
Yasuda, SU ;
Dans, PE ;
Wright, A ;
Califf, RM ;
Woosley, RL ;
Schulman, KA .
AMERICAN JOURNAL OF MEDICINE, 2003, 114 (02) :135-141
[17]   KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome [J].
Donger, C ;
Denjoy, I ;
Berthet, M ;
Neyroud, N ;
Cruaud, C ;
Bennaceur, M ;
Chivoret, G ;
Schwartz, K ;
Coumel, P ;
Guicheney, P .
CIRCULATION, 1997, 96 (09) :2778-2781
[18]   Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart [J].
Drici, MD ;
Burklow, TR ;
Haridasse, V ;
Glazer, RI ;
Woosley, RL .
CIRCULATION, 1996, 94 (06) :1471-1474
[19]   Mechanism of arrhythmogenicity of the short-long cardiac sequence that precedes ventricular tachyarrhythmias in the long QT syndrome [J].
El-Sherif, N ;
Caref, EB ;
Chinushi, M ;
Restivo, M .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (05) :1415-1423
[20]   The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome - Tridimensional mapping of activation and recovery patterns [J].
ElSherif, N ;
Caref, EB ;
Yin, H ;
Restivo, M .
CIRCULATION RESEARCH, 1996, 79 (03) :474-492
12345678